Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Pain. 2021 Sep 1;162(9):2386–2396. doi: 10.1097/j.pain.0000000000002229

Table 2.

Baseline ongoing activity in animals treated with vehicle, FAc, or L-AA.

C Combined population
Control (n = 21); 0.05 (0.23) (n = 32); 0.77 (1.4) 0.16 (1.18)
FAc (n = 10); 0.08 (0.50) (n = 8); 0.88 (1.83) 0.16 (1.23)
L-AA (n = 7); 0.1 (0.70) (n = 8); 0.85 (1.18) 0.77 (0.98)

Data are expressed as median (IQR). N represent the number of afferents tested (1 afferent/animal). Ongoing activity (in spikes/sec) is based on data collected for at least 45 minutes before CSD. Group differences were analyzed using 2-tailed Kruskal–Wallis test and were not significant (P > 0.05) for the population tested.

FAc, fluoroacetate; L-AA, L-α-aminoadipate.